Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Invion ( (AU:IVX) ) is now available.
Invion Limited has made significant progress in its cancer treatment programs, highlighted by a $20,000 grant from the Colorectal Surgical Society of Australia and New Zealand Foundation to support an upcoming anogenital cancer clinical trial in collaboration with the Peter MacCallum Cancer Centre. The company has also advanced to Part 2 of its Phase I/II non-melanoma skin cancer trial, which showed promising early efficacy and potential diagnostic benefits. Additionally, Invion launched a Loyalty Option Entitlement Offer, raising approximately $1 million, with potential further funding if all options are exercised. These developments underscore Invion’s commitment to advancing its clinical programs and strengthening its financial position.
More about Invion
Invion Limited is a company operating in the biotechnology industry, focusing on developing treatments for cancer. The company is engaged in clinical trials and research, particularly in the areas of skin and anogenital cancers, leveraging innovative diagnostic and therapeutic techniques.
Average Trading Volume: 114,306
Technical Sentiment Signal: Sell
Current Market Cap: A$8.2M
See more data about IVX stock on TipRanks’ Stock Analysis page.